Retatrutide

Retatrutide (LY3437943) is a novel triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors. This tri-agonist approach represents the next evolution in incretin-based pharmacology, building on dual agonism by incorporating glucagon receptor activity. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure, enhance hepatic lipid oxidation, and promote thermogenesis, while the GIP and GLP-1 components provide appetite suppression and improved glycemic control.

The glucagon receptor component of retatrutide's activity profile is of particular scientific interest. Glucagon receptor agonism promotes hepatic glycogenolysis and gluconeogenesis, which under normal circumstances would elevate blood glucose. However, the concurrent GIP and GLP-1 receptor agonism appears to counterbalance this hyperglycemic potential while allowing the metabolic benefits of glucagon signaling — including increased energy expenditure, lipolysis, and amino acid catabolism — to be harnessed.

Preclinical studies in rodent models have demonstrated that rationally designed triple agonist peptides produce superior metabolic outcomes compared to dual or single agonists, including greater body weight reduction, improved glucose tolerance, and reduced hepatic steatosis. These findings have generated substantial research interest in tri-agonism as a pharmacological strategy.